1664OA randomized non-comparative phase II study of anti–PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 trial. (23rd October 2018) - Pujol, J-L; Greillier, L; Audigier Valette, C; Moro-Sibilot, D; Uwer, L; Hureaux, J; Thiberville, L; Carmier, D; Madelaine, J; Otto, J; Gounant, V; Merle, P; et al.